Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of ISIS 560131 in AR-V7-positive metastatic castration-resistant prostate cancer
ChiCTR2100044174Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD5312 in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: PSA and Tumor imaging and survival-related assessments. Started Dec 2020; status: recruiting.
02
Drugs
AZD5312
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2100044174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044174.